Creative Diagnostics offers high‑sensitivity ELISAs

Creative Diagnostics said in January it released a portfolio of high-sensitivity ELISA kits designed to detect antibiotic residues and related process impurities in biologics manufacturing. The New York-based supplier markets the kits for use in quality-control workflows covering raw materials, intermediate products and final biologic products. Company materials say the assays are intended for trace detection of antibiotics used during cell culture and other upstream production steps. The product push sits in a narrow but established part of biologics analytics: checking whether antibiotics introduced during production have been removed to acceptable levels before release or further processing. Creative Diagnostics says the kits are suitable for samples including cell lysate, serum, urine, recombinant protein and fermentation liquid, and positions them as tools for impurity detection during bioproduction. (creative-diagnostics.com) ### Which problem are these ELISAs meant to solve inside biologics production? Creative Diagnostics says antibiotic residues are “common cell culture-derived impurities” in biological production and that residue screening is critical because leftover antibiotics may affect drug safety and quality. The company links that need to impurity control requirements described in ICH Q6B, the guideline covering test procedures and acceptance criteria for biotechnological and biological products. (creative-diagnostics.com) ICH says manufacturers should characterize and control product- and process-related impurities in biologics, including materials introduced during production. Creative Diagnostics cites that framework in describing its kits as part of monitoring and controlling process-related contaminants during bioproduction. ### What exactly is Creative Diagnostics offering? (qbd.creative-diagnostics.com) Creative Diagnostics lists a panel of antibiotics ELISA kits and related impurity-detection products on its biologics quality-by-design pages. The company says the assays are built for quantitative analysis of antibiotic residues and names antibiotics such as gentamicin, kanamycin and neomycin in product descriptions carried on company and syndication pages. (creative-diagnostics.com) The company also says the kits are validated in a range of biological samples and have lot-to-lot consistency. In its product materials, Creative Diagnostics describes the assays as high sensitivity and says measured-value reproducibility is above 80%. ### Why use ELISA here instead of a mass-spectrometry method? Creative Diagnostics says ELISA offers a faster and easier workflow than LC-MS/MS for some impurity-testing applications. (qbd.creative-diagnostics.com) In company materials, it describes the kits as a high-throughput and cost-effective alternative for screening antibiotic residues in biologics-related samples. (creative-diagnostics.com) That comparison comes from the company, not an independent head-to-head study in the materials reviewed. Creative Diagnostics’ own blog says LC-MS/MS remains the more information-rich approach in some settings, while presenting ELISA as useful for routine screening and assay workflows where speed and throughput matter. ### Where would these kits fit in a lab workflow? (creative-diagnostics.com) Creative Diagnostics says the kits are intended for quality-control and assay-validation work in biomanufacturing and analytical laboratories. The company’s product pages place them alongside raw-material reagents and analytical services for biological-drug quality control and process-related impurity testing. The marketed use case is not patient diagnostics. (creative-diagnostics.com) The materials reviewed describe the assays as manufacturing and research tools for monitoring antibiotic carryover across production stages and checking whether purification has reduced residues to required levels. ### What should readers watch next? Creative Diagnostics’ current product and support pages are the next place to watch for additions to the antibiotic panel, sample-validation claims or updated performance data. (qbd.creative-diagnostics.com) As of this week, the company continues to list antibiotics ELISA kits, antimicrobial ELISA kits and support materials tied to biologics impurity testing on its website. (qbd.creative-diagnostics.com 1) (qbd.creative-diagnostics.com 2)